Brainstorm Cell Therapeutics(BCLI) - 2025 Q4 - Annual Report

Clinical Trials and Regulatory Status - NurOwn® has completed Phase 3 clinical trials for ALS and Phase 2 trials for PMS, with top-line data announced on November 17, 2020, and March 24, 2021, respectively[14]. - The FDA issued a refusal to file (RTF) letter for the Biologics License Application (BLA) for NurOwn® on November 10, 2022, prompting a Type A meeting to discuss the RTF content[15]. - The Advisory Committee voted on September 27, 2023, with 17 voting no, one yes, and one abstention, indicating that NurOwn® did not demonstrate substantial evidence of effectiveness for mild to moderate ALS[15]. - The BLA for NurOwn® was withdrawn on November 3, 2023, in coordination with the FDA, and is considered a withdrawal without prejudice[15]. - A Special Protocol Assessment (SPA) request for a planned Phase 3b clinical trial was submitted to the FDA on February 23, 2024, and written agreement on the trial design was received on April 9, 2024[32]. - The FDA issued a Refusal to File (RTF) letter regarding the BLA for NurOwn®, citing insufficient evidence of effectiveness and CMC-related items[50]. - Following the RTF, the company requested a Type A meeting with the FDA to discuss the letter's contents and potential pathways for regulatory review[52]. - The company plans to file the BLA for NurOwn® over Protest to expedite the review process[54]. - The Phase 3 trial enrolled a broad set of participants, including those with advanced ALS, which may have impacted the sensitivity of the ALSFRS-R[51]. - The FDA's Advisory Committee voted 17 against, 1 in favor, and 1 abstention regarding the effectiveness of NurOwn® for treating mild to moderate ALS on September 27, 2023[66]. - The company announced the withdrawal of the BLA for NurOwn® on November 3, 2023, which was coordinated with the FDA and considered a withdrawal without prejudice[66]. - The company received written agreement from the FDA on April 9, 2024, under a Special Protocol Assessment (SPA) for the design of a Phase 3b trial of NurOwn® in ALS[66]. Clinical Efficacy and Safety - Completed two Phase 1/2 open-label trials of NurOwn® in ALS patients, demonstrating tolerability and preliminary signs of activity[33]. - Phase 2 trial involved 48 patients randomized 3:1 to receive NurOwn® or placebo, with no discontinuations due to adverse events[36]. - NurOwn® treatment showed a higher response rate in the ALS functional rating scale compared to placebo, with significant improvements in muscle volume and pulmonary function[35]. - In the Phase 3 trial, 32.6% of NurOwn® participants met the primary endpoint of at least a 1.25 points per month improvement in ALSFRS-R slope, compared to 27.7% for placebo[48]. - A statistically significant treatment difference (p=0.050) was observed in a pre-specified subgroup with ALSFRS-R baseline scores of at least 35, showing an average change of -1.56 on NurOwn® versus -3.65 on placebo[51]. - Clinical analyses indicated that NurOwn® treatment resulted in significant increases in neurotrophic factors and reductions in inflammatory markers, correlating with functional improvements[44]. - The Phase III trial for NurOwn® did not meet its overall primary endpoint, but patients with ALSFRS scores above 35 showed a two-point higher score than those on placebo at the trial's end[166]. - The Phase 2 clinical trial of NurOwn® for PMS showed that 80% of the 20 enrolled patients completed the study, with no deaths or serious adverse events related to MS worsening[77]. - 38% of NurOwn® treated patients demonstrated at least a 10-point improvement in the MS Walking Scale (MSWS-12) from baseline to week 28[81]. - 67% of NurOwn® treated patients exhibited at least a 3-point improvement in the Symbol Digit Modality Test (SDMT), indicating enhanced cognitive processing[81]. Technology and Manufacturing - The NurOwn® technology platform utilizes autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete neurotrophic factors, promoting neuronal survival and improving neurological function[22]. - The proprietary technology and manufacturing process for NurOwn® are conducted in compliance with current Good Manufacturing Practice[24]. - The company has developed a validated cryopreservation process for MSC, allowing multiple doses of NurOwn® from a single bone marrow harvest[56]. - The company contracted with City of Hope and Dana Farber Cancer Institute for the manufacturing of clinical supplies of NurOwn® for the Phase 3 clinical study[57]. - The company announced a partnership with Catalent for the manufacturing of NurOwn® if FDA approval is received, with technology transfer completed in December 2021[58][59]. - The company has improved the efficiency and stability of NurOwn® production, allowing centralized manufacturing and distribution to clinical trial sites[106]. Financial and Funding - The company received a total of $15,912,390 in non-dilutive funding from the California Institute for Regenerative Medicine (CIRM) for its Phase 3 study of NurOwn® for ALS[85]. - The company employs 20 individuals across the United States and Israel, with a focus on recruiting and retaining talent to support its clinical development goals[20]. - The company holds approximately 30 granted patents and has pending applications across key global markets, including the U.S., Europe, and South America[88]. - The U.S. Patent & Trademark Office granted a Notice of Allowance for a patent covering proprietary exosome technology, expected to provide protection until April 10, 2039[89]. - The company maintains a commercial relationship with Ramot at Tel Aviv University, paying royalties of 3%-5% on net sales derived from licensed intellectual property[132]. Market and Regulatory Environment - The company aims to secure regulatory approval for NurOwn® in ALS, with a potential Biologics License Application (BLA) submission following the completion of its Phase 3b clinical trial[113]. - NurOwn® has been designated as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency (EMA)[129]. - The FDA regulates the approval process for biological products, which requires substantial time and financial resources, with no certainty of timely approvals for stem cell therapies[138]. - The FDA has 60 days from receipt of a Biologics License Application (BLA) to determine if the application will be accepted for filing, which is based on whether it is sufficiently complete for substantive review[147]. - The FDA targets ten months for the initial review of standard applications for original BLAs and six months for applications granted priority review, although these timelines are not always met[150]. - The approval process may require additional clinical data or other information, and the FDA may issue a Complete Response Letter detailing deficiencies in the BLA[154]. - The company must incur significant expenditures in training, record keeping, production, and quality control to ensure compliance with current Good Manufacturing Practice (cGMP) requirements[152]. - Fast Track designation allows the FDA to review sections of the marketing application on a rolling basis if certain conditions are met, potentially expediting the approval process[161]. - The company must submit annual safety reports detailing adverse events identified during clinical trials to the FDA[143]. - The FDA may require Phase 4 testing to further assess a biologic's safety and effectiveness after BLA approval[156]. - The company must develop methods for testing the identity, strength, quality, and purity of the final product during the manufacturing process[144]. - The FDA may grant orphan designation to a drug intended to treat a rare disease affecting fewer than 200,000 individuals in the U.S., providing benefits such as grant funding and tax credits[158]. Legislative and Market Challenges - The Act for ALS, signed into law on December 23, 2021, authorized up to $100 million per year for 5 years, totaling $500 million for research on neurodegenerative diseases like ALS[165]. - The FDA's Action Plan for Rare Neurodegenerative Diseases, released on June 23, 2022, outlines a five-year strategy to enhance scientific achievement and innovation in ALS drug development[166]. - Increased funding through government programs, such as ACT for ALS, has elevated focus on ALS research and expedited therapy development[169]. - The company faces uncertainty regarding insurance coverage and reimbursement for newly approved products, which could limit marketability and revenue generation[179]. - Legislative changes focused on cost containment and price transparency may impact the company's ability to sell stem cell therapies profitably[182]. - The pharmaceutical industry is expected to face pricing pressures due to managed healthcare trends and legislative proposals, which could adversely affect the company's operations[184]. - Third-party payors increasingly require pre-approval for new therapies and may demand predetermined discounts, impacting the reimbursement landscape for stem cell therapies[185]. - In the EU, pricing and reimbursement rules significantly influence pharmaceutical product pricing, with some countries requiring clinical trials to demonstrate cost-effectiveness[186]. - The downward pressure on healthcare costs has created high barriers for new product entry, with cross-border imports from low-priced markets affecting local pricing[189]. - Compliance with various healthcare laws, including the federal Anti-Kickback Statute and False Claims Act, is critical to avoid penalties and ensure operational integrity[190]. - The Patient Protection and Affordable Care Act has increased minimum Medicaid rebates and imposed mandatory discounts for Medicare Part D beneficiaries, affecting reimbursement for medical products[207]. - The Budget Control Act of 2011 mandates up to 2% reductions in Medicare payments to providers annually, effective through 2031 unless Congress intervenes[208]. - The Inflation Reduction Act of 2022 introduces a $2,000 out-of-pocket cap for Medicare Part D beneficiaries starting in 2025 and allows the government to negotiate price caps for certain high-cost drugs[212]. - Legislative changes may lead to additional reductions in Medicare funding and affect pricing for product candidates awaiting regulatory approval[208]. - The company is monitoring developments related to the 340B drug pricing program, which may expand patient access to discounted medications[211]. - Increased scrutiny on specialty drug pricing practices may lead to new transparency requirements and cost control measures in the healthcare industry[209]. - The company may incur financial liabilities under the new provisions of the Inflation Reduction Act, particularly regarding drug price increases[212]. - Ongoing litigation challenges the constitutionality of the Medicare drug price negotiation program, with uncertain implications for the company's operations[212].